JP2024542879A - Pd-1およびtgf-brii結合ドメインを含む多重特異性結合部位 - Google Patents

Pd-1およびtgf-brii結合ドメインを含む多重特異性結合部位 Download PDF

Info

Publication number
JP2024542879A
JP2024542879A JP2024524389A JP2024524389A JP2024542879A JP 2024542879 A JP2024542879 A JP 2024542879A JP 2024524389 A JP2024524389 A JP 2024524389A JP 2024524389 A JP2024524389 A JP 2024524389A JP 2024542879 A JP2024542879 A JP 2024542879A
Authority
JP
Japan
Prior art keywords
seq
heavy chain
amino acid
tgf
binding site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542879A5 (cg-RX-API-DMAC7.html
Inventor
セシリア アンナ ヴィルヘルミナ ジェウイジェン
パトリック メイズ
ショーン エム. スチュワート
リアンーチュワン ワン
Original Assignee
メルス ナムローゼ フェンノートシャップ
インサイト コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス ナムローゼ フェンノートシャップ, インサイト コーポレーション filed Critical メルス ナムローゼ フェンノートシャップ
Publication of JP2024542879A publication Critical patent/JP2024542879A/ja
Publication of JP2024542879A5 publication Critical patent/JP2024542879A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024524389A 2021-11-19 2022-11-18 Pd-1およびtgf-brii結合ドメインを含む多重特異性結合部位 Pending JP2024542879A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19
NL2029844 2021-11-19
PCT/EP2022/082377 WO2023089083A1 (en) 2021-11-19 2022-11-18 Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Publications (2)

Publication Number Publication Date
JP2024542879A true JP2024542879A (ja) 2024-11-18
JP2024542879A5 JP2024542879A5 (cg-RX-API-DMAC7.html) 2025-03-11

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524389A Pending JP2024542879A (ja) 2021-11-19 2022-11-18 Pd-1およびtgf-brii結合ドメインを含む多重特異性結合部位

Country Status (18)

Country Link
US (1) US20230159645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433505A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542879A (cg-RX-API-DMAC7.html)
KR (1) KR20240101664A9 (cg-RX-API-DMAC7.html)
CN (2) CN119613560A (cg-RX-API-DMAC7.html)
AR (1) AR127714A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022389596A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231649A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001410A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006325A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240201A (cg-RX-API-DMAC7.html)
EC (1) ECSP24039278A (cg-RX-API-DMAC7.html)
IL (1) IL312214A (cg-RX-API-DMAC7.html)
MX (1) MX2024006018A (cg-RX-API-DMAC7.html)
PE (1) PE20241477A1 (cg-RX-API-DMAC7.html)
TW (1) TW202328180A (cg-RX-API-DMAC7.html)
UY (1) UY40028A (cg-RX-API-DMAC7.html)
WO (1) WO2023089083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121152809A (zh) * 2023-04-14 2025-12-16 因赛特公司 抗TGFβR2/PD-1双特异性抗体治疗癌症的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532280A (ja) * 2017-07-06 2020-11-12 メルス ナムローゼ フェンノートシャップ 細胞により発現される生物学的活性を調節する結合分子
WO2021133167A1 (en) * 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN110198738A (zh) * 2017-01-07 2019-09-03 默克专利有限公司 用于靶向的TGF-β抑制的给药方案和剂型
TWI887193B (zh) * 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020532280A (ja) * 2017-07-06 2020-11-12 メルス ナムローゼ フェンノートシャップ 細胞により発現される生物学的活性を調節する結合分子
WO2021133167A1 (en) * 2019-12-24 2021-07-01 Merus N.V. Tgf-beta-rii binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIQIN LIU ET AL., CANCER RESEARCH, vol. Vol. 81, No. 13_Supplement, JPN6025027459, 1 July 2021 (2021-07-01), pages 693 - 693, ISSN: 0005785709 *

Also Published As

Publication number Publication date
AU2022389596A1 (en) 2024-05-30
ECSP24039278A (es) 2024-07-31
PE20241477A1 (es) 2024-07-17
CL2024001410A1 (es) 2024-08-30
MX2024006018A (es) 2024-07-29
CN119613560A (zh) 2025-03-14
AR127714A1 (es) 2024-02-21
TW202328180A (zh) 2023-07-16
US20230159645A1 (en) 2023-05-25
CA3231649A1 (en) 2023-05-25
IL312214A (en) 2024-06-01
KR20240101664A9 (ko) 2025-12-10
CN118265725A (zh) 2024-06-28
EP4433505A1 (en) 2024-09-25
KR20240101664A (ko) 2024-07-02
CR20240201A (es) 2024-07-15
WO2023089083A1 (en) 2023-05-25
CO2024006325A2 (es) 2024-06-27
UY40028A (es) 2023-05-31

Similar Documents

Publication Publication Date Title
JP7803907B2 (ja) メソテリン及びcd137結合分子
JP2023015262A (ja) ヒトcd137に結合するアゴニスト性抗体およびその使用
US11505599B2 (en) T cell receptor-like antibodies specific for Foxp3-derived peptides
JP2024149487A (ja) ホスファターゼ動員による受容体の阻害
US12286483B2 (en) Method of treating cancer using CD137 antibodies and PD-1 antagonists
TW201741337A (zh) CD40L-Fc融合多肽及其使用方法
KR20210030406A (ko) Cd137 항원-결합 부위를 포함하는 fc 결합 단편
CN107835820A (zh) 识别癌症特异性IL13Rα2的CAR T细胞
JP2019515656A (ja) キメラ抗原受容体
KR20230020421A (ko) Cd70 특이적 융합 단백질을 사용하는 tcr 재프로그래밍을 위한 조성물 및 방법
JP2021518138A (ja) 抗il−27抗体及びその使用
KR20220148699A (ko) 항-cntn4 특이적 항체 및 그의 용도
JP6527644B1 (ja) 抗pd−l1−抗tim−3二重特異性抗体
KR20230008144A (ko) Cd19를 표적화하는 키메라 항원 수용체 및 그의 용도
US20210355220A1 (en) Antibodies specific to ctla-4 and uses thereof
US20230159645A1 (en) Multispecific binding moieties comprising pd-1 and tgf-brii binding domains
JP2022518441A (ja) ヒトcd137に結合する抗体の製剤およびその使用
US20240141070A1 (en) Ox40/pd-l1 bispecific antibody
TW202506711A (zh) 切換受體
WO2024103251A1 (zh) 抗afp/hla02 tcr样抗体及其用途
HK40110611A (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
HK40119948A (en) Humanized antibody that bonds to eva1 protein or functional fragment thereof, antibody-drug conjugate and chimeric antigen receptor
HK40070619B (en) Anti-hk2 chimeric antigen receptor (car)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260202

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20260513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260706

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260728